PE20221049A1 - Metodos para preparar analogos de incretina - Google Patents
Metodos para preparar analogos de incretinaInfo
- Publication number
- PE20221049A1 PE20221049A1 PE2022000273A PE2022000273A PE20221049A1 PE 20221049 A1 PE20221049 A1 PE 20221049A1 PE 2022000273 A PE2022000273 A PE 2022000273A PE 2022000273 A PE2022000273 A PE 2022000273A PE 20221049 A1 PE20221049 A1 PE 20221049A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- preparing
- methods
- nos
- incretin analogs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Abstract
SE REFIERE A UN METODO PARA PREPARAR UN ANALOGO DE INCRETINA DE SEQ ID NO: 6, EL CUAL COMPRENDE LA ETAPA DE ACOPLAR, MEDIANTE SINTESIS EN FASE HIBRIDA SOLIDA LIQUIDA, CUATRO COMPUESTOS INTERMEDIARIOS SELECCIONADOS DE LOS GRUPOS QUE CONSISTEN EN: A. SEQ ID NOS: 7, 8, 9 Y 10, B. SEQ ID NOS: 7, 11, 12 Y 10, Y C. SEQ ID NOS: 7, 13, 14 Y 10; EN DICHO METODO TAMBIEN SE PUEDE ACOPLAR, MEDIANTE SINTESIS EN FASE HIBRIDA SOLIDA LIQUIDA, DOS O TRES COMPUESTOS INTERMEDIARIOS. TAMBIEN SE REFIERE A LOS COMPUESTOS INTERMEDIARIOS DE SEQ ID NO: 7 A 28 Y 38 A 40.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962888756P | 2019-08-19 | 2019-08-19 | |
| PCT/US2020/046778 WO2021034815A1 (en) | 2019-08-19 | 2020-08-18 | Methods of making incretin analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221049A1 true PE20221049A1 (es) | 2022-06-30 |
Family
ID=72322545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022000273A PE20221049A1 (es) | 2019-08-19 | 2020-08-18 | Metodos para preparar analogos de incretina |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220411461A1 (es) |
| EP (1) | EP4017866A1 (es) |
| JP (1) | JP2022545200A (es) |
| KR (1) | KR20220035199A (es) |
| CN (1) | CN114269775A (es) |
| AU (1) | AU2020334993B2 (es) |
| BR (1) | BR112022001081A2 (es) |
| CA (1) | CA3148347A1 (es) |
| CL (1) | CL2022000374A1 (es) |
| CO (1) | CO2022001413A2 (es) |
| EC (1) | ECSP22013340A (es) |
| IL (1) | IL289957A (es) |
| MX (1) | MX2022002115A (es) |
| PE (1) | PE20221049A1 (es) |
| WO (1) | WO2021034815A1 (es) |
| ZA (1) | ZA202200948B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| CN117642153A (zh) | 2021-05-07 | 2024-03-01 | 伊莱利利公司 | 易蚀片剂 |
| TW202404996A (zh) * | 2022-04-04 | 2024-02-01 | 美商美國禮來大藥廠 | 製備glp-1/升糖素雙重促效劑之方法 |
| CN115368234B (zh) * | 2022-08-19 | 2024-01-26 | 淄博矿业集团有限责任公司 | 一种索马鲁肽侧链及其中间体的合成方法 |
| WO2024077149A2 (en) | 2022-10-05 | 2024-04-11 | Eli Lilly And Company | Peptides for incretin synthesis |
| WO2024112617A2 (en) * | 2022-11-21 | 2024-05-30 | Eli Lilly And Company | Process for preparing a gip/glp1 dual agonist |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110046349A1 (en) | 2009-07-15 | 2011-02-24 | Matthieu Giraud | Process for the production of exenatide and of an exenatide analogue |
| EP2844669B1 (en) | 2012-05-03 | 2018-08-01 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| WO2014049610A2 (en) | 2012-09-26 | 2014-04-03 | Cadila Healthcare Limited | Peptides as gip, glp-1 and glucagon receptors triple-agonist |
| PE20151770A1 (es) * | 2013-05-28 | 2015-12-11 | Takeda Pharmaceutical | Compuesto peptidico |
| EP3066117B1 (en) | 2013-11-06 | 2019-01-02 | Zealand Pharma A/S | Glucagon-glp-1-gip triple agonist compounds |
| CN103613656B (zh) * | 2013-11-20 | 2015-03-04 | 陕西东大生化科技有限责任公司 | 一种艾塞那肽的固相片段合成方法 |
| JOP20200119A1 (ar) | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| KR20170080521A (ko) | 2015-12-31 | 2017-07-10 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 |
| KR20220150416A (ko) | 2016-03-10 | 2022-11-10 | 메디뮨 리미티드 | 비만 치료를 위한 글루카곤 및 glp-1 공동-작용제 |
| AR110301A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip |
| CN106749610A (zh) * | 2016-12-29 | 2017-05-31 | 陕西慧康生物科技有限责任公司 | 一种艾塞那肽的制备方法及其产品 |
| TWI744579B (zh) * | 2017-12-21 | 2021-11-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| TWI767095B (zh) | 2017-12-21 | 2022-06-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| EP3827015A1 (en) | 2018-07-23 | 2021-06-02 | Eli Lilly and Company | Gip/glp1 co-agonist compounds |
-
2020
- 2020-08-18 CA CA3148347A patent/CA3148347A1/en active Pending
- 2020-08-18 EP EP20765144.9A patent/EP4017866A1/en active Pending
- 2020-08-18 US US17/633,631 patent/US20220411461A1/en active Pending
- 2020-08-18 WO PCT/US2020/046778 patent/WO2021034815A1/en unknown
- 2020-08-18 BR BR112022001081A patent/BR112022001081A2/pt unknown
- 2020-08-18 JP JP2022510146A patent/JP2022545200A/ja active Pending
- 2020-08-18 AU AU2020334993A patent/AU2020334993B2/en active Active
- 2020-08-18 CN CN202080059063.8A patent/CN114269775A/zh active Pending
- 2020-08-18 MX MX2022002115A patent/MX2022002115A/es unknown
- 2020-08-18 KR KR1020227005160A patent/KR20220035199A/ko not_active Application Discontinuation
- 2020-08-18 PE PE2022000273A patent/PE20221049A1/es unknown
-
2022
- 2022-01-18 IL IL289957A patent/IL289957A/en unknown
- 2022-01-20 ZA ZA2022/00948A patent/ZA202200948B/en unknown
- 2022-02-11 CO CONC2022/0001413A patent/CO2022001413A2/es unknown
- 2022-02-15 CL CL2022000374A patent/CL2022000374A1/es unknown
- 2022-02-18 EC ECSENADI202213340A patent/ECSP22013340A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2022000374A1 (es) | 2022-11-18 |
| CN114269775A (zh) | 2022-04-01 |
| CO2022001413A2 (es) | 2022-03-18 |
| KR20220035199A (ko) | 2022-03-21 |
| EP4017866A1 (en) | 2022-06-29 |
| BR112022001081A2 (pt) | 2022-05-24 |
| US20220411461A1 (en) | 2022-12-29 |
| MX2022002115A (es) | 2022-03-17 |
| AU2020334993A1 (en) | 2022-02-24 |
| IL289957A (en) | 2022-03-01 |
| CA3148347A1 (en) | 2021-02-25 |
| ECSP22013340A (es) | 2022-03-31 |
| WO2021034815A1 (en) | 2021-02-25 |
| AU2020334993B2 (en) | 2023-07-13 |
| JP2022545200A (ja) | 2022-10-26 |
| ZA202200948B (en) | 2024-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20221049A1 (es) | Metodos para preparar analogos de incretina | |
| AR123811A2 (es) | Composiciones de células madre mesenquimáticas purificadas y métodos relacionados | |
| ECSP20070854A (es) | Compuestos heteroaril tetracíclicos | |
| PE20191043A1 (es) | Composicion farmaceutica | |
| CL2017003258A1 (es) | Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| CR20180323A (es) | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 | |
| MX2016012984A (es) | Derivados indol para uso en medicina. | |
| BR112015023036A2 (pt) | método para preparar um produto alcaloide benzilisoquinolina e célula microbiana engenheirada que produz um produto alcaloide benzilisoquinolina | |
| AR105963A1 (es) | Procedimiento para la purificación de hidrolizado de biomasa | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| CL2019002297A1 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos. | |
| CL2019002190A1 (es) | Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) | |
| BR112017000805A2 (pt) | método para extração de proteínas solúveis de biomassa de microalgas | |
| AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
| MX2016007128A (es) | Compuestos del receptor 6 de quimiocina (ccr6). | |
| EA201791058A1 (ru) | Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) | |
| CL2018000182A1 (es) | Compuesto que se dirige a il-23a y al factor de activación de linfocitos b (baff) y usos de estos | |
| CY1121147T1 (el) | Νεες συντηγμενες ενωσεις ιμιδαζοβενζοθειαζολιου | |
| MX2020004869A (es) | Metodo para preparar derivado de benzofurano. | |
| EA201591795A1 (ru) | Бицикло[2.2.1]-кислоты в качестве модуляторов рецептора gpr120 | |
| PE20211243A1 (es) | Procedimiento y productos intermedios para la preparacion de bilastina | |
| EA201791396A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ | |
| BR112017007949A2 (pt) | método para produção de álcool pelo uso de uma tripeptidil-peptidase | |
| BR112017023820A2 (pt) | ?uso de pelo menos um composto, método de recuperação de pelo menos uma terra rara e composto da fórmula específica? | |
| EA201792234A1 (ru) | Новые соединения пиридиния |